Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC

(MedPage Today) -- NEW ORLEANS--Neoadjuvant combinations involving durvalumab (Imfinzi) plus novel agents led to major pathological responses (MPRs) in nearly a third of patients with early-stage non-small cell lung cancer (NSCLC), a phase...